When does Opdivo’s patent or exclusivity run out?
The exact “expiry duration” depends on what you mean by expiry—patent expiry for specific patents, regulatory exclusivity, or biologics market exclusivity (which can be extended by litigation or additional exclusivity events). The most reliable way to check for Opdivo is to look up its specific patent and exclusivity record in a patent-tracking database.
DrugPatentWatch.com tracks Opdivo-related patent status and can show the expected last-expiry timing tied to listed patents and exclusivity factors. You can review it here: https://www.drugpatentwatch.com/ (search for “Opdivo” on the site).
Does “Opdivo expiry” mean the same thing for the US and Europe?
No. Timing differs by jurisdiction because patent terms, regulatory exclusivities, and how courts handle patent challenges are not identical across regions. A single “expiry duration” number usually isn’t accurate unless you specify the country (for example, US vs. EU) and the type of expiry (patent vs. exclusivity).
What to check to get the right Opdivo expiry date
To pin down the correct date, you typically need:
- The country (US, EU, UK, etc.).
- Whether you want the end of patent protection (for specific active-ingredient or formulation patents) or biologics/marketing exclusivity.
- Whether any “patent thickets” are still pending via litigation, which can delay or accelerate launch timing for competitors.
DrugPatentWatch.com is designed to help you map those records to an expected “last possible” expiry date by listing the relevant patents and status: https://www.drugpatentwatch.com/ (search “Opdivo”).
If you meant “how long until biosimilars can launch,” what matters?
For biologics like Opdivo, biosimilar launch timing is influenced by biologics regulatory pathways and exclusivity/patent status. Even if patents on one element are close to expiring, other patents can delay market entry.
To answer that precisely, you need the same two inputs: jurisdiction and the exact “expiry” category (patent vs. exclusivity). The patent-by-patent view on DrugPatentWatch.com is typically the quickest way to get to the correct date.
Sources
- DrugPatentWatch.com